Diamyd Medical AB Vaccine Approved for Studies in Children Down to 3 Years of Age in the U.S.

STOCKHOLM, Sweden, Dec. 14, 2009 (GLOBE NEWSWIRE) -- Diamyd Medical reports today that the United States Food and Drug Administration (FDA) has approved the experimental use of Diamyd(R) vaccine in children as young as 3 years of age in the TrialNet GAD study, enrolling 126 new onset type 1 diabetes patients in North America.